Cellular therapy in lymphoma

Anna Sureda; Pieternella J. Lugtenburg; Marie José Kersten; Marion Subklewe; Anne Spanjaart; Nirali N. Shah; Lucila N. Kerbauy; Clarie Roddie; Elise R. A. Pennings; Carolina Mahuad; Michelle Poon; Candice L. Hendricks; Manali Kamdar; Caron Jacobson

doi:https://doi.org/10.1002/hon.3200

Cellular therapy in lymphoma

Anna Sureda, Pieternella J. Lugtenburg, Marie José Kersten, Marion Subklewe, Anne Spanjaart, Nirali N. Shah, Lucila N. Kerbauy, Clarie Roddie, Elise R. A. Pennings, Carolina Mahuad, Michelle Poon, Candice L. Hendricks, Manali Kamdar, Caron Jacobson

Research output: Contribution to journal › Review article › Academic › peer-review

4 Citations (Scopus)

Abstract

CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a dramatic impact on the natural history and survival of patients with high-risk B-cell non-Hodgkin lymphoma. Accompanying this success has been the development of new fields of medicine and investigation into toxicity risks and mitigation therapies, mechanisms of resistance and the development of novel and next generation products and strategies in order to address relapse, and issues related to global access and health care economics. This article is a survey of each of these areas as it pertains to the rapidly evolving field of CAR T-cell therapy, written by an International community of lymphoma experts, who also happen to be women.

Original language	English
Journal	Hematological oncology
Early online date	2023
DOIs	https://doi.org/10.1002/hon.3200
Publication status	E-pub ahead of print - 2023

Keywords

CAR T-cells
lymphoma

Access to Document

https://doi.org/10.1002/hon.3200

Cite this

@article{4db467dc17b443468ccb58d71fcd9ef6,

title = "Cellular therapy in lymphoma",

abstract = "CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a dramatic impact on the natural history and survival of patients with high-risk B-cell non-Hodgkin lymphoma. Accompanying this success has been the development of new fields of medicine and investigation into toxicity risks and mitigation therapies, mechanisms of resistance and the development of novel and next generation products and strategies in order to address relapse, and issues related to global access and health care economics. This article is a survey of each of these areas as it pertains to the rapidly evolving field of CAR T-cell therapy, written by an International community of lymphoma experts, who also happen to be women.",

keywords = "CAR T-cells, lymphoma",

author = "Anna Sureda and Lugtenburg, {Pieternella J.} and Kersten, {Marie Jos{\'e}} and Marion Subklewe and Anne Spanjaart and Shah, {Nirali N.} and Kerbauy, {Lucila N.} and Clarie Roddie and Pennings, {Elise R. A.} and Carolina Mahuad and Michelle Poon and Hendricks, {Candice L.} and Manali Kamdar and Caron Jacobson",

note = "Publisher Copyright: {\textcopyright} 2023 John Wiley & Sons Ltd.",

year = "2023",

doi = "https://doi.org/10.1002/hon.3200",

language = "English",

journal = "Hematological oncology",

issn = "0278-0232",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Cellular therapy in lymphoma

AU - Sureda, Anna

AU - Lugtenburg, Pieternella J.

AU - Kersten, Marie José

AU - Subklewe, Marion

AU - Spanjaart, Anne

AU - Shah, Nirali N.

AU - Kerbauy, Lucila N.

AU - Roddie, Clarie

AU - Pennings, Elise R. A.

AU - Mahuad, Carolina

AU - Poon, Michelle

AU - Hendricks, Candice L.

AU - Kamdar, Manali

AU - Jacobson, Caron

PY - 2023

Y1 - 2023

N2 - CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a dramatic impact on the natural history and survival of patients with high-risk B-cell non-Hodgkin lymphoma. Accompanying this success has been the development of new fields of medicine and investigation into toxicity risks and mitigation therapies, mechanisms of resistance and the development of novel and next generation products and strategies in order to address relapse, and issues related to global access and health care economics. This article is a survey of each of these areas as it pertains to the rapidly evolving field of CAR T-cell therapy, written by an International community of lymphoma experts, who also happen to be women.

AB - CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a dramatic impact on the natural history and survival of patients with high-risk B-cell non-Hodgkin lymphoma. Accompanying this success has been the development of new fields of medicine and investigation into toxicity risks and mitigation therapies, mechanisms of resistance and the development of novel and next generation products and strategies in order to address relapse, and issues related to global access and health care economics. This article is a survey of each of these areas as it pertains to the rapidly evolving field of CAR T-cell therapy, written by an International community of lymphoma experts, who also happen to be women.

KW - CAR T-cells

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85164144382&partnerID=8YFLogxK

U2 - https://doi.org/10.1002/hon.3200

DO - https://doi.org/10.1002/hon.3200

M3 - Review article

C2 - 37382086

SN - 0278-0232

JO - Hematological oncology

JF - Hematological oncology

ER -

Cellular therapy in lymphoma

Abstract

Keywords

Access to Document

Other files and links

Cite this